Q3 2017 13F Holders as of 30 Sep 2017
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
15,329,891
-
Share change
-
+1,303,444
-
Total reported value
-
$238,826,580
-
Price per share
-
$15.58
-
Number of holders
-
75
-
Value change
-
+$20,971,742
-
Number of buys
-
49
-
Number of sells
-
20
Institutional Holders of JOUNCE THERAPEUTICS INC - COM (JNCE) as of Q3 2017
As of 30 Sep 2017,
JOUNCE THERAPEUTICS INC - COM (JNCE) was held by
75 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
15,329,891 shares.
The largest 10 holders included
FMR LLC, WELLINGTON MANAGEMENT GROUP LLP, Partner Fund Management, L.P., Redmile Group, LLC, BlackRock Inc., Pharmstandard International S.A., Omega Fund Management, LLC, VANGUARD GROUP INC, BROWN ADVISORY INC, and Casdin Capital, LLC.
This page lists
75
institutional shareholders reporting positions in this security
for the Q3 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.